Endovia Health Sciences, Inc. (EDVA)
| Market Cap | 1.11M -57.0% |
| Revenue (ttm) | 32,090 -90.9% |
| Net Income | -18.84M |
| EPS | -13.60 |
| Shares Out | 6.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 446,043 |
| Open | 0.1761 |
| Previous Close | 0.1700 |
| Day's Range | 0.1740 - 0.1801 |
| 52-Week Range | 0.1344 - 6.7600 |
| Beta | -1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 28, 2026 |
About EDVA
Endovia Health Sciences, Inc. develops a diversified cannabinoid health sciences platform that translates science into regulated therapies and trusted health and wellness products for people and animals in Ireland, United Kingdom, Australia, and Latin America. Its product includes CannEpil a pharmaceutical-grade cannabinoid formulation comprising cannabidiol and tetrahydrocannabinol isolates in an oral liquid solution. Endovia Health Sciences, Inc. formerly known as Splash Beverage Group, Inc. The company is based in Fort Lauderdale, Florida.
Financial Performance
In 2025, Endovia Health Sciences's revenue was $73,066, a decrease of -90.88% compared to the previous year's $801,273. Losses were -$26.07 million, 9.72% more than in 2024.
Financial StatementsNews
Endovia Health Sciences Proxy statement: Proxy filing
Endovia Health Sciences filed a proxy statement on November 2, 2026, providing details for shareholder voting and corporate governance matters.
Endovia Health Sciences registers to sell 1.01M shares of common for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.01M shares of common stock. The company is not selling any…
Endovia Health Sciences Registration statement: Registration filing
Endovia Health Sciences filed a registration statement on October 27, 2026, providing details about a securities offering with the SEC.
Endovia Health Sciences Proxy statement: Proxy filing
Endovia Health Sciences filed a proxy statement on October 23, 2026, providing details for shareholder voting and corporate governance matters.
Endovia Health Sciences Proxy statement: Proxy filing
Endovia Health Sciences filed a proxy statement on October 8, 2026, providing details for shareholder voting and corporate governance matters.
Endovia Health Sciences announces FDA minor-use determination for CannEpil
Endovia Health Sciences (EDVA) announced the FDA Center for Veterinary Medicine determined that the proposed use of CannEpil, an investigational CBD and THC oral solution for control of pain associate...
Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway
FORT LAUDERDALE, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (“Endovia” or the “Company”) (NYSE American: EDVA), in association with Lupvindol BioSciences (“Lupvindol”), toda...
Endovia Health Sciences Proxy statement: Proxy filing
Endovia Health Sciences filed a proxy statement on October 5, 2026, providing details for shareholder voting and corporate governance matters.
Endovia Health Sciences Proxy statement: Proxy filing
Endovia Health Sciences filed a proxy statement on September 23, 2026, providing details for shareholder voting and corporate governance matters.
Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways
Endovia financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived medicines
Endovia Health Sciences Proxy statement: Proxy filing
Endovia Health Sciences filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline
Endovia Health Sciences believes the federal government's affirmative support for Schedule III represents a significant evolution in U.S. cannabinoid poli
Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program
FORT LAUDERDALE, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (NYSE American: EDVA), formerly Splash Beverage Group, Inc. (NYSE American: SBEV) ("Endovia Health" or the "Compa...
Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday
FORT LAUDERDALE, Fla., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the “Company”) today announced that its corporate name will change to Endovia Health Science...
Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences
FORT LAUDERDALE, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today reported financial results for the second quarter ended Jun...
Endovia Health Sciences Registration statement: Registration filing
Endovia Health Sciences filed a registration statement on August 20, 2026, providing details about a securities offering with the SEC.
Endovia Health Sciences Quarterly report: Q2 2026
Endovia Health Sciences has published its Q2 2026 quarterly earnings report on August 19, 2026.
Endovia Health Sciences Earnings release: Q2 2026
Endovia Health Sciences released its Q2 2026 earnings on August 19, 2026, summarizing the period's financial results.
Splash Beverage Group to Rebrand as Endovia Health Sciences
FORT LAUDERDALE, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the "Company") today announced its intention to change its corporate name to Endovia Health ...
Endovia Health Sciences Registration statement: Registration filing
Endovia Health Sciences filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Splash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil® Through FDA Veterinary Pathway
Collaboration with Lupvindol Biosciences will initially target companion-animal oncology and chronic pain management Splash retains ownership of resulting data, intellectual property and commercializa...
Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program
Splash expands its exclusive global license for CannEpil® to include veterinary applications, creating a second regulated pharmaceutical development platfo
Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation
SPLASH announces significant actions designed to strengthen the Company's financial position and advance its previously announced NYSE compliance plan.
Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation
FORT LAUDERDALE, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) ("Splash," "Splash Beverage" or the "Company") today announced that NYSE American has accepte...
Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential
$SBEV announces licensing agreement with Argent BioPharma for CannEpil®, a proprietary, cannabinoid-based therapeutic for the treatment of epilepsy (DRE)